Published in Blood Weekly, July 18th, 2002
"Imatinib mesylate (STI571) is a promising new treatment for chronic myelogenous leukemia (CML)," according to Dr. Melissa S. Holtz and colleagues at the City of Hope National Medical Center in Duarte, California, and the University of California at Los Angeles.
Although this agent does not trigger the death of CML progenitor cells, it removes the competitive advantage they have over healthy stem cells, Holtz and coauthors found.
Proliferation of progenitor cells...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.